Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent signed by the patient and guardian.~* Positive clinical history of allergy to dust mites.~* FEV1 greater than or equal to 80% of the expected value and improvement in FEV1 greater than 12% after bronchodilation.~* Age-between 5 and 14 years.~* Sensitization to dust mites, diagnosed by positive skin tests to Dermatophagoides pteronyssinus: wheal size \> 3 mm diameter and / or RAST (\> 0.7 kU / L).~Exclusion Criteria:~* Patients out of the age range.~* Use of immunotherapy during the last four years.~* Any contraindication for the use of immunotherapy in accordance with European Allergy and Clinical Immunology Immunotherapy Subcommittee criteria:~  * Treatment with ß-blockers~ * Patients who have a condition in which adrenaline is contraindicated (hyperthyroidism, hypertension, heart disease, etc..).~ * Coexistence of immunopathological diseases (e.g. of the liver, kidney, the nervous system, thyroid gland, rheumatic diseases) in which autoimmune mechanisms play a role~ * Patients suffering from immune deficiencies~ * Patients with serious psychiatric / psychological disturbances~* Patients aspirin intolerance

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Subcutaneous administration
- B (Type: EXPERIMENTAL): Sublingual administration
- C (Type: PLACEBO_COMPARATOR): Sublingual administration

Based on this trial design, predict the completion outcome and termination type (if applicable).